Finance

Lists
LYEL:NASDAQ
Lyell Immunopharma Inc
$12.87
-0.54%
(-0.070) 1D
$12.87
0.00% (0.00)
After hours
Closed: Aug 3, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LYEL...
Open
$13.05
High
$13.15
Low
$12.71
Mkt. cap
300.31M
Avg. vol.
226.27K
Volume
86.02K
52-wk high
$45.00
52-wk low
$9.28
EPS
-$12.98
Beta
-0.06
Shares outstanding
24.50M
No. of employees
161
Open
$13.05
High
$13.15
Low
$12.71
Mkt. cap
300.31M
Avg. vol.
226.27K
Volume
86.02K
52-wk high
$45.00
52-wk low
$9.28
EPS
-$12.98
Beta
-0.06
Shares outstanding
24.50M
No. of employees
161
News stories
From sources across the web
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitelyell.com
Analyst ratings
Based on 4 analysts giving stock ratings to LYEL in the past 3 months
Buy
Buy
3
Hold
0
Sell
1
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for LYEL in the last 3 months.
Highest
Current $12.87
$45.00 (+249.65%)
Average
$36.25 (+181.66%)
Lowest
$12.00 (-6.76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yuan Zhi
B. Riley Securities
Buy
Initiated
$44.00
+241.9%
07/22/2026
Gil Blum
Needham
Buy
Maintained
$44.00
+241.9%
06/15/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+249.7%
06/09/2026
Jason Zemansky
Bank of America Securities
Sell
Reiterated
$12.00
-6.8%
06/03/2026
Jack Allen
Robert W. Baird
Buy
Initiated
$49.00
+280.7%
05/01/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$34.00
+164.2%
03/09/2026
Next call in 9 days
Wed, Aug 12, 12:30 PM
Fiscal period
Q2 2026
EPS / Est. (USD)
- / -
Revenue / Est. (USD)
- / 3.83K
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
8.00K
15.00K
6.00K
2.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
34.86M
28.17M
52.20M
36.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.79M
10.69M
10.62M
9.56M
Operating expense
43.30M
37.27M
61.48M
44.26M
Total operating expenses
43.30M
37.27M
61.48M
44.26M
Operating income
-43.30M
-37.25M
-61.48M
-44.26M
Other non operating income
1.18M
-4.86M
-17.46M
17.91M
EBT including unusual items
-42.68M
-38.85M
-140.72M
-24.15M
EBT excluding unusual items
-38.84M
-38.85M
-76.26M
-24.15M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-1.34M
-1.59M
-1.33M
-1.90M
Net income
-42.68M
-38.85M
-140.72M
-24.15M
Net profit margin
-533,550.00%
-258,973.33%
-2,345,383.33%
-1,207,650.00%
Earnings per share
-
-
-
-
Interest and investment income
3.28M
3.27M
2.68M
2.19M
Interest expense
-
-
-
-
Net interest expenses
3.28M
3.27M
2.68M
2.19M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.16M
-34.69M
-59.08M
-41.93M
Gain or loss from assets sale
2.47M
-249.00K
-166.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps